Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Retreatment for 24 vs 48 weeks with interferon-alpha 2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone
Autore:
Enriquez, J; Gallego, A; Torras, X; Perez-Olmeda, T; Diago, M; Soriano, V; Lujan, MS; Garcia-Samaniego, J;
Indirizzi:
Hosp Sta Creu & St Pau, Dept Gastroenterol, Barcelona 08025, Spain Hosp Sta Creu & St Pau Barcelona Spain 08025 rol, Barcelona 08025, Spain Hosp Carlos III, Madrid, Spain Hosp Carlos III Madrid SpainHosp Carlos III, Madrid, Spain Hosp Gen Univ, Valencia, Spain Hosp Gen Univ Valencia SpainHosp Gen Univ, Valencia, Spain
Titolo Testata:
JOURNAL OF VIRAL HEPATITIS
fascicolo: 6, volume: 7, anno: 2000,
pagine: 403 - 408
SICI:
1352-0504(200011)7:6<403:RF2V4W>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
COMBINATION THERAPY; RANDOMIZED TRIAL; HCV RNA; VIRUS; EFFICACY; PLACEBO; ALPHA; ALFA;
Keywords:
hepatitis C; interferon; relapse; ribavirin; treatment;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Enriquez, J Hosp Sta Creu & St Pau, Dept Gastroenterol, C Antoni Marta Claret 167, Barcelona 08025, Spain Hosp Sta Creu & St Pau C Antoni Marta Claret 167 Barcelona Spain 08025
Citazione:
J. Enriquez et al., "Retreatment for 24 vs 48 weeks with interferon-alpha 2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone", J VIRAL HEP, 7(6), 2000, pp. 403-408

Abstract

We assessed the efficacy of interferon (IFN) plus ribavirin over 24 or 48 weeks for the retreatment of patients with chronic hepatitis C who had relapsed or did not respond to a previous course of IFN, One-hundred and twentypatients (69 non-responders and 51 relapsers) were randomly assigned to receive IFN-alpha 2b (3 million units thrice weekly) plus ribavirin (1000-1200 mg per day) for 24 weeks (group A: 58 patients) or 48 weeks (group B: 62 patients). Treatment was discontinued at week 12 if the alanine aminotransferase (ALT) level remained elevated. The rate of sustained response was 15.5% in group A and 37.1% in group B (P = 0.013), Relapsers treated for 48 weeks had a sustained response rate of 66.6% compared with a sustained response rate of only 25% in those treated for 24 weeks (P = 0.004). Moreover, a sustained response was seen in 14.3% of non-responders treated for 48 weeksand in 8.8% of those treated for 24 weeks (P = 0.71). Fifty-three per centof patients with a normal ALT level and undetectable hepatitis C virus (HCV) RNA at week 12 had a sustained response compared with 14% of those who were HCV RNA positive at week 12 (P < 0.001). Independent predictive factorsof sustained response were: therapy for 48 weeks (P = 0.0026), relapse after IFN treatment (P = 0.0006), loss of HCV RNA at week 12 (P = 0.0008) and HCV genotype non-1 (P = 0.024). Hence, in patients with chronic hepatitis Cwho failed to respond to a previous course of IFN monotherapy, combinationtherapy with IFN plus ribavirin for 48 weeks seems to be more effective than IFN plus ribavirin for 24 weeks.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 21:54:02